



CLAIM AMENDMENTS

1. (Currently Amended) A composition comprising:
a vaccine preparation effective for treatment of a mammal in unit dosage form
including:
an effective amount of an antigen;
an adjuvant component comprising phytol, isophytol, or a phytol derivative, said
antigen homogenously dispersed in the adjuvant component; and optionally a carrier.
2. (Original) The composition of claim 1 wherein the adjuvant component comprises phytol.
3. (Original) The composition of claim 1 wherein the adjuvant component comprises isophytol.
4. (Original) The composition of claim 1 wherein the adjuvant component comprises phytanol.
5. (Original) The composition of claim 1 wherein the adjuvant component comprises a phytol derivative selected from the group consisting of: phytanol; 1-chloro-3,7,11,15-tetramethyl hexadec-2-ene; iodo-3,7,11,15-tetramethyl hexadeca-2-ene; 1-amino-3,7,11,15-tetramethyl hexadec-2-ene; 3,7,11,15-tetramethyl-hexadec-2-en-1-al; 3,7,11,15-tetramethyl-1-hexadecanal; 3,7,11,15-tetramethyl-1-hexadec-2-enyl acetate; 3,7,11,15-tetramethyl-1-hexadecanyl acetate; 1-chloro-3,7,11,15-tetramethyl hexadecane; 1-iodo-3,7,11,15-tetramethyl hexadecane; 1-amino-3,7,11,15-tetramethyl hexadecane; 1-methyl amino-3,7,11,15-tetramethyl hexadecane; stereoisomers and mixtures thereof.

6. (Original) The composition of claim 1 wherein the adjuvant component comprises phytol or a phytol derivative of the formula I or II:



wherein R¹ is selected from the group of chemical moieties, ions, or radicals consisting of: Br⁻, Cl⁻; I⁻; -NH₂, -NO₂, OH, PO₄⁼, HPO₄⁻, NHR², OC(O)R², OR², wherein R² is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate.

7. (Original) The composition of claim 1 wherein the antigen includes a T-independent antigen.

8. (Original) The composition of claim 7 wherein the antigen is selected from the group consisting of: polysaccharides, pneumococcus polysaccharides, bacterial lipopolysaccharides, synthetic lipopolysaccharides, and hapten-polysaccharide conjugates.

9. (Original) The composition of claim 1 wherein the antigen includes a T-dependent antigen.

10. (Currently Amended) The composition of claim 9 wherein the antigen is selected from the group consisting of: proteins, peptides, lipoproteins, glycoproteins, ~~gangliosides~~ gangliosides, cerebroside, nucleoproteins, eukaryotic cellular isolates, and prokaryotic cellular isolates.


11. (Original) The composition of claim 1 wherein the carrier is sterile water at pH 7.0.

12. (Currently Amended) The composition of claim 1 wherein the carrier is comprises physiological buffers that include carbonates, bicarbonates, phosphates.
13. (Original) The composition of claim 1 wherein the vaccine composition is an oil-in-water emulsion.
14. (Original) The composition of claim 13 comprising a surfactant or emulsifier.
15. (Currently Amended) The composition of claim 14 wherein the emulsifier is selected from the group consisting of: phospholipids ~~such as phosphoglycerides,~~ lysophosphoglycerides, spingomyelin, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol and mixtures thereof.
16. (Original) The composition of claim 1 wherein the vaccine composition comprises the phytol or the phytol derivative and the antigen in a weight ratio of between about 1:4 to about 1:1.
- 17-26. (Canceled)
27. (Original) A composition comprising a vaccine preparation in unit dosage form including an effective amount of an antigen conjugated directly to phytanol or a phytol derivative and a surfactant mixed in equal volume, and optionally a carrier or buffer solution.
28. (Original) The composition of claim 27 comprising between 4 and 100 micrograms of the antigen conjugated directly to phytanol or a phytol derivative.
29. (Original) The composition of claim 27 comprising between about 0.05 to about 0.1 % (wt/v) of the surfactant.

30. (Previously Presented) A composition comprising:
a vaccine preparation in unit dosage form including:
an effective amount of an antigen;
an adjuvant component comprising a phytol derivative; and optionally a liquid carrier.

31. (Previously Presented) The composition of claim 30 wherein the adjuvant component comprises a phytol derivative selected from the group consisting of: phytanol; 1-chloro-3,7,11,15-tetramethyl hexadec-2-ene; iodo-3,7,11,15-tetramethyl hexadeca-2-ene; 1-amino-3,7,11,15-tetramethyl hexadec-2-ene; 3,7,11,15-tetramethyl-hexadec-2-en-1-al; 3,7,11,15-tetramethyl-1-hexadecanal; 3,7,11,15-tetramethyl-1-hexadec-2-enyl acetate; 3,7,11,15-tetramethyl-1-hexadecanyl acetate; 1-chloro-3,7,11,15-tetramethyl hexadecane; 1-iodo-3,7,11,15-tetramethyl hexadecane; 1-amino-3,7,11,15-tetramethyl hexadecane; 1-methyl amino-3,7,11,15-tetramethyl hexadecane; stereoisomers and mixtures thereof.

32. (Previously Presented) The composition of claim 30 wherein the adjuvant component comprises a phytol derivative of the formula I:



wherein R¹ is selected from the group of chemical moieties, ions, or radicals consisting of: Br⁻, Cl⁻, I⁻; -NH₂, -NO₂, OH, PO₄⁼, HPO₄⁻, NHR², OC(O)R², and OR², wherein R² is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate.

33. (Previously Presented) The composition of claim 32 wherein R¹ is selected from -NH₂ or NHR² wherein R² is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate.

34. (Previously Presented) The composition of claim 32 wherein R¹ is selected from the group of chemical moieties consisting of: OH, OC(O)R², and OR², wherein R² is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate.

35. (Previously Presented) The composition of claim 32 wherein R^1 is selected from the group of chemical moieties consisting of: OH , $PO_4^{=}$, and HPO_4^- .

36. (Previously Presented) The composition of claim 32 wherein R^1 is selected from the group of chemical moieties consisting of: Br^- , Cl^- ; and I^- .


37. (Previously Presented) The composition of claim 32 comprising an emulsifier selected from the group consisting of: phospholipids such as phosphoglycerides, lysophosphoglycerides, spingomyelin, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol and mixtures thereof.

38. (Previously Presented) The composition of claim 32 comprising a surfactant selected from the group consisting of: mannide monooleates, 1,4-sorbitan, mono- and triesters, and polyoxyethylene derivatives of stearic acid.

39. (Previously Presented) The composition of claim 32 wherein the antigen is selected from the group consisting of: polysaccharides, pneumococcus polysaccharides, bacterial lipopolysaccharides, synthetic lipopolysaccharides, and hapten-polysaccharide conjugates.

40. (Previously Presented) The composition of claim 32 wherein the antigen is selected from the group consisting of: proteins, peptides, lipoproteins, glycoproteins, gangliosides, cerebroside, nucleoproteins, eukaryotic cellular isolates, and prokaryotic cellular isolates.

41. (Previously Presented) The composition of claim 30 wherein the adjuvant component comprises a phytol derivative of the formula II:



wherein R^1 is selected from the group of chemical moieties, ions, or radicals consisting of: Br^- , Cl^- ; I^- ; $-NH_2$, $-NO_2$, OH , $PO_4^{=}$, HPO_4^- , NHR^2 , $OC(O)R^2$, OR^2 , wherein R^2 is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate.

42. (Previously Presented) The composition of claim 41 wherein R^1 is selected from $-NH_2$ or NHR^2 wherein R^2 is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate.

43. (Currently Amended) The composition of claim 41 wherein R^1 is selected from the group of ~~chemical~~ chemical moieties consisting of: OH , $OC(O)R^2$, and OR^2 , wherein R^2 is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate.

44. (Currently Amended) The composition of claim 41 wherein R^1 is selected from the group of ~~chemical~~ chemical moieties consisting of: OH , $PO_4^{=}$, and HPO_4^- .

45. (Previously Presented) The composition of claim 41 wherein R^1 is selected from the group of chemical moieties consisting of: Br^- , Cl^- ; and I^- .

46. (Previously Presented) The composition of claim 41 comprising an emulsifier selected from the group consisting of: phosphoglycerides, lysophosphoglycerides, spingomyelin, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol and mixtures thereof.

47. (Previously Presented) The composition of claim 41 comprising a surfactant selected from the group consisting of: mannide monooleates, 1,4-sorbitan, mono- and triesters, and polyoxyethylene derivatives of stearic acid.

48. (Previously Presented) The composition of claim 41 wherein the antigen is selected from the group consisting of: polysaccharides, pneumococcus polysaccharides, bacterial lipopolysaccharides, synthetic lipopolysaccharides, and hapten-polysaccharide conjugates.

49. (Previously Presented) The composition of claim 41 wherein the antigen is selected from the group consisting of: proteins, peptides, lipoproteins, glycoproteins, gangliosides, cerebroside, nucleoproteins, eukaryotic cellular isolates, and prokaryotic cellular isolates.

50. (Previously Presented) A method of enhancing the immunogenicity of a vaccine composition, said method comprising:
selecting an antigen eliciting a desired immunogenic response in a mammal, and
combining the antigen with the phytol derivative of claim 32 in a physiological acceptable carrier.


51. (Currently Amended) A method of treating a patient, said method comprising:
~~said method comprising:~~
preparing a vaccine formulation containing an antigen eliciting a desired immunogenic response in a mammal, and combining the antigen with the phytol derivative of claim 32 in a physiological acceptable carrier; and
administering the vaccine formulation to the patient.

52. (Previously Presented) A method of enhancing the immunogenicity of a vaccine composition, said method comprising:
selecting an antigen eliciting a desired immunogenic response in a mammal, and
combining the antigen with the phytol derivative of claim 41 in a physiological acceptable carrier.


53. (Currently Amended) A method of treating a patient, said method comprising:
~~said method comprising:~~

preparing a vaccine formulation containing an antigen eliciting a desired immunogenic response in a mammal, and combining the antigen with the phytol derivative of claim 41 in a physiological acceptable carrier; and
administering the vaccine formulation to the patient.

54. (New) The composition of claim 1 wherein the adjuvant component comprises phytol or a phytol derivative of the formula I or II:




I




II

wherein R¹ is selected from the group of ions consisting of: Br⁻, Cl⁻, and I⁻.

55. (New) The composition of claim 1 wherein the adjuvant component comprises phytol or a phytol derivative of the formula I or II:




I




II

wherein R^1 is selected from the group of chemical moieties consisting of: $-NH_2$, $-NO_2$, and NHR^2 , wherein R^2 is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate

56. (New) The composition of claim 1 wherein the adjuvant component comprises phytol or a phytol derivative of the formula I or II:



I



II

wherein R^1 is selected from the group of chemical moieties, ions, or radicals consisting of: OH , $OC(O)R^2$, OR^2 , wherein R^2 is a hydrocarbyl having 1 to 10 carbon atoms or a carbohydrate.